Novo Nordisk A/S (ETR:NOV)

Market Cap	173.33B
Revenue (ttm)	42.26B
Net Income (ttm)	13.89B
Shares Out	n/a
EPS (ttm)	3.12
PE Ratio	12.47
Forward PE	11.67
Dividend	1.56 (3.94%)
Ex-Dividend Date	Aug 15, 2025

Volume	598,500
Average Volume	405,705
Open	40.65
Previous Close	40.35
Day's Range	38.89 - 43.62
52-Week Range	38.51 - 107.00
Beta	0.33
RSI	19.70
Earnings Date	Nov 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK